CorMedix Inc. Overview
Pro stress-test →CorMedix is commercializing DefenCath (taurolidine and heparin), an antimicrobial catheter lock solution approved by the U.S. Food and Drug Administration to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in a limited population of adult patients with kidney failure receiving chronic hemodialysis via a central venous catheter. The company reported net revenue and net income for the quarter ended September 30, 2025, driven primarily by product sales of DefenCath and the Melinta portfolio.
Strategic Profile
Pro stress-test →CorMedix reported positive adjusted EBITDA and increased its full-year 2025 pro forma net revenue guidance. The company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL, providing diversified revenue streams beyond its lead product.
Competitive Landscape
Pro stress-test →CorMedix operates in the antimicrobial catheter lock solution market with DefenCath as its flagship product targeting hemodialysis patients. The company faces competition from established pharmaceutical players and other anti-infective developers in the broader infection prevention space. Its Melinta portfolio addition diversifies into broad-spectrum antibiotics, competing against major pharma players.
Industry Context
CorMedix Inc. operates in Biopharmaceuticals / Anti-Infective Therapeutics.
Key facts
Founded: 2006 · Headquarters: Berkeley Heights, New Jersey, US · Revenue: $40.3M gross profit TTM · Market cap: $919M